Menu Search
Equities

XBiotech Inc

4XB:MUN

XBiotech Inc

Actions
  • Price (EUR)6.90
  • Today's Change-0.70 / -9.21%
  • Shares traded200.00
  • 1 Year change+85.48%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 07:04 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year XBiotech Inc had revenues fall -100.00% from 4.01m to 0.00, though the company grew net income from a loss of 32.90m to a smaller loss of 24.56m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-15.53%
Return on equity-16.44%
Return on investment-16.32%
More ▼

Cash flow in USDView more

In 2023, XBiotech Inc increased its cash reserves by 27.16%, or 42.72m. Cash Flow from Investing totalled 61.50m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 18.73m for operations while cash used for financing totalled 9.00k.
Cash flow per share-1.09
Price/Cash flow per share--
Book value per share6.46
Tangible book value per share6.46
More ▼

Balance sheet in USDView more

XBiotech Inc appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio11.13
Quick ratio--
Total debt/total equity0.0508
Total debt/total capital0.0484
More ▼

Growth rates in USD

SmartText is unavailable
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		-23.15
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.